@VanProstateCtr profile picture
Vancouver Prostate Centre @VanProstateCtr

A National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Joined November 2011
  • Tweets 1,552
  • Following 130
  • Followers 1,242
208 Photos and videos
You can also stay up to date by following us on our other platforms! šŸ”— LinkedIn: linkedin.com/company/prostatā€¦ šŸ”— Facebook: facebook.com/share/16gUypbMqā€¦ šŸ”— We are excited to announce we will have additional channels coming soon!

Vancouver Prostate Centre | LinkedIn

Vancouver Prostate Centre | 1,799 followers on LinkedIn. Comprehensive in-house research outpatient clinic, hosting an extensive translational research program | The mission of the Vancouver...

linkedin.com
1
269
High-risk #ProstateCancer patients may benefit from precision-tailored neoadjuvant therapy. Dr. Martin E. Gleave, CM, MD, FRCSC, FACS, Director, Vancouver Prostate Centre, explains the GUNS trial, now enrolling 280 patients.
1
2
12
4,316
šŸŒWatch the full discussion here: urotoday.com/.../5443-guns-tā€¦... šŸŒRead the VPC News Here! urotoday.com/.../5443-guns-tā€¦...
1
149
New research in Nature CommunicationsĀ from investigators at the Vancouver Prostate CentreĀ shows plasma ctDNA testing is a valuable adjunct to tissue testing for detecting FGFR alterations in metastatic urothelial cancer and may identify additional patients eligible for therapy.
2
7
381
šŸŒClick here for the VPC News: prostatecentre.com/news/vancā€¦ šŸŒClick here to read the full study: nature.com/articles/s41467-0ā€¦
1
68
#CancerResearch #PrecisionMedicine #MedTwitter
1
34
Congratulations to Dr. Ewan Gibb, from theĀ Vancouver Prostate Centre,Ā on his latest publication in European Urology Oncology! Dr. Ewan Gibb introduces a long non-coding RNA classifierĀ that helps identify hidden biological risk in early low-grade bladder cancer.
1
3
102
ā€œThis classifier could help clinicians see which tumors may recur despite appearing low-risk,ā€ says Dr. Gibb. This work advances personalized bladder cancer careĀ and adds critical insight for intermediate-risk patients.
1
1
57
šŸŒClick here for the VPC News: prostatecentre.com/news/dr-eā€¦ šŸŒClick here for the Publication: euoncology.europeanurology.cā€¦
1
64
CongratulationsĀ to Dr. Nada Lallous on being selected as a delegate for Science Meets Parliament BC 2026! Proud to see VPC researchers contributing to science-informed policy and health innovation. Full announcement:šŸ”— sciencepolicy.ca/programs/scā€¦ VPC NEWS:šŸ”— prostatecentre.com/news/dr-nā€¦
2
73
New paper from Dr. Alex Wyatt and his team: increased clonal hematopoiesis observed following radioligand therapy in mCRPC. Led by PhD student Asli Munzur and in collaboration with ANZUP trial group in Australia. šŸŒ Read here: doi.org/10.1158/1078-0432.CCā€¦
1
1
60
Congratulations Alex, Asli, and team! #ProstateCancer #LuPSMA #CancerResearch
1
31
Vancouver Prostate Centre is pleased to announce $1.01M in CIHR funding awarded to Dr. Alex Wyatt to advance circulating tumor DNA (ctDNA) biomarkers for treatment response in metastatic prostate cancer. šŸ”—Read more on VPC News! prostatecentre.com/news/dr-aā€¦
1
1
65
šŸ”— CIHR Project Details: webapps.cihr-irsc.gc.ca/deciā€¦ #ProstateCancer #CancerResearch #ProstateCancerTreatment
1
44
Congratulations to Dr. Yuzhuo Wang on receiving $1.26M in CIHR fundingĀ to study aggressive neuroendocrine prostate cancer (NEPC), focusing on key regulators PROX1Ā and CHD7.Congrats Read more on VPC News! šŸ”—: prostatecentre.com/news/dr-yā€¦ #ProstateCancer #vancouverprostatecentre
1
2
118
New research from the Vancouver Prostate Centre, led by Dr. Dong Gao, published in JCI Insight, shows how UGT2B17 drives resistance to androgen deprivation therapy through non-canonical mechanisms. PMID: 41343245 pubmed.ncbi.nlm.nih.gov/4134ā€¦

Noncanonical functions of UGT2B17 promote castration-resistant prostate cancer progression - PubMed

Androgen deprivation therapy is the primary treatment for advanced prostate tumors. While initially effective, tumor progression to the therapy-resistant stage is inevitable. Paradoxically, UDP...

pubmed.ncbi.nlm.nih.gov
1
1
3
425
Related 2025 work in European Urology Oncology further supports UGT2B17 as a promising therapeutic target in treatment-resistant prostate cancer. PMID: 40998686 pubmed.ncbi.nlm.nih.gov/4099ā€¦

Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in...

UGT2B17 expression influences hormone levels and identifies a subset of patients at an increased risk of progression to an incurable disease stage. Findings support the notion that enhanced UGT2B17,...

pubmed.ncbi.nlm.nih.gov
1
51
Researchers at the Vancouver Prostate Centre, led by Prof. Wilfred A. Jefferies, have developed Gemini, a self-amplifying vaccine and nanomedicine platform designed to overcome key limitations of current mRNA technologies. šŸ”— nature.com/articles/s41467-0ā€¦

1
1
2
83
#GeminiPlatform #VaccineTech #saRNA #saDNA #mRNAalternatives #Cancer #GlobalHealth #SARS_COV_2 #COVID_19 @UBC @Nature @GenomeBC @CIHR_IRSC @BioSScotland @JamesHuttonInst @ISED_CA @GovCanHealth
1
97
Proud moment for the Vancouver Prostate Centre!!! ā€” a high majority of the 2026 PCFC Grant-in-Aid recipientsĀ are affiliated with VPC! Thank you @ProstateCanada for supporting impactful prostate cancer initiatives. šŸ”— Read the full announcement: prostatecanada.ca/news/2026-ā€¦

Prostate Cancer Foundation Canada

Providing leadership & resources in prostate cancer support, awareness, & research since 1997. Now proudly supporting patients and loved ones across Canada.

prostatecanada.ca
1
2
65
Dr. Peter Black, Director of the Vancouver Prostate Centre, is leading research using proteomic profiling to advance precision treatment strategies for severe bladder cancer. Learn more about the work being done at VPC: prostatecentre.com/news/advaā€¦ #BladderCancer #CancerResearch
1
2
62
Load more